CHINA NEW HLDGS (08125) plans to offer approximately 14.4% of its shares for sale, with a maximum of 20.68 million shares available. The net proceeds are expected to be around HKD 7.41 million.
China New Holdings Limited (08125) announced that on July 22, 2026 (after trading hours), the Company entered into a placing agreement with the placing agent, pursuant to which the placing agent has agreed to place a maximum of 20.6821 million new shares at a placing price of HK$0.385 per share on behalf of the Company to no fewer than six independent placees on a best effort basis.
CHINA NEW HLDGS (08125) announced that on July 22, 2026 (after the trading session), the company entered into a placing agreement with the placing agent. According to the agreement, the placing agent has agreed to place a maximum of 20.6821 million new shares on behalf of the company to not less than six independent placees at a placing price of HK$0.385 per share.
The placing price of HK$0.385 per share represents a discount of approximately 14.4% to the closing price of HK$0.45 per share on the GEM on July 22, 2026 (the date of the placing agreement).
The placing is subject to approval or approval for the listing and trading of the placing shares by the Stock Exchange Listing Committee. If the conditions are not met, the placing will not proceed.
The maximum of 20.6821 million placing shares represents approximately 10.55% of the company's total issued share capital of 196 million shares as of the date of the announcement, and approximately 9.54% of the company's total issued share capital after the placing.
The net proceeds from the placing of approximately HK$7.41 million (assuming full allocation of placing shares and deduction of all related expenses) are intended for use as working capital and for future investments of the group when opportunities arise. However, specific investment targets have not yet been determined as of the date of the announcement.
Related Articles

Chongqing Changan Automobile (000625.SZ) has received approval from the Shenzhen Stock Exchange for its application to issue A shares to specific investors.

ASCLETIS-B(01672) will report in oral form at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) that the weight loss effect of ASC36_35 FDC is superior to the preclinical data of eloralintide combined with tirzepatide.

Alphabet Inc. Class C (GOOGL.US) Q2 cloud revenue soared 82%, but capital expenditure is set to skyrocket to $205 billion, scaring the market with negative cash flow for the first time ever.
Chongqing Changan Automobile (000625.SZ) has received approval from the Shenzhen Stock Exchange for its application to issue A shares to specific investors.

ASCLETIS-B(01672) will report in oral form at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) that the weight loss effect of ASC36_35 FDC is superior to the preclinical data of eloralintide combined with tirzepatide.

Alphabet Inc. Class C (GOOGL.US) Q2 cloud revenue soared 82%, but capital expenditure is set to skyrocket to $205 billion, scaring the market with negative cash flow for the first time ever.

RECOMMEND





